246 related articles for article (PubMed ID: 11276276)
1. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease.
Nousia-Arvanitakis S; Fotoulaki M; Economou H; Xefteri M; Galli-Tsinopoulou A
J Clin Gastroenterol; 2001 Apr; 32(4):324-8. PubMed ID: 11276276
[TBL] [Abstract][Full Text] [Related]
2. Delayed intestinal visualization at hepatobiliary scintigraphy is associated with response to long-term treatment with ursodeoxycholic acid in patients with cystic fibrosis-associated liver disease.
Colombo C; Crosignani A; Battezzati PM; Castellani MR; Comi S; Melzi ML; Giunta A
J Hepatol; 1999 Oct; 31(4):672-7. PubMed ID: 10551391
[TBL] [Abstract][Full Text] [Related]
3. Use of ursodeoxycholic acid in patients with liver disease.
Angulo P
Curr Gastroenterol Rep; 2002 Feb; 4(1):37-44. PubMed ID: 11825540
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid for cystic fibrosis-related liver disease.
Cheng K; Ashby D; Smyth RL
Cochrane Database Syst Rev; 2014 Dec; (12):CD000222. PubMed ID: 25501301
[TBL] [Abstract][Full Text] [Related]
5. Ursodeoxycholic acid for cystic fibrosis-related liver disease.
Cheng K; Ashby D; Smyth RL
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD000222. PubMed ID: 28891588
[TBL] [Abstract][Full Text] [Related]
6. Liver disease in cystic fibrosis.
Colombo C; Apostolo MG; Assaisso M; Roman B; Bottani P
Neth J Med; 1992 Oct; 41(3-4):119-22. PubMed ID: 1470280
[TBL] [Abstract][Full Text] [Related]
7. Hepatic Manifestations of Cystic Fibrosis.
Sakiani S; Kleiner DE; Heller T; Koh C
Clin Liver Dis; 2019 May; 23(2):263-277. PubMed ID: 30947876
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic acid therapy in hepatobiliary disease.
Kowdley KV
Am J Med; 2000 Apr; 108(6):481-6. PubMed ID: 10781781
[TBL] [Abstract][Full Text] [Related]
9. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
[TBL] [Abstract][Full Text] [Related]
10. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.
Desmond CP; Wilson J; Bailey M; Clark D; Roberts SK
Liver Int; 2007 Dec; 27(10):1402-8. PubMed ID: 18036103
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid therapy in cystic fibrosis liver disease--a retrospective long-term follow-up case-control study.
Kappler M; Espach C; Schweiger-Kabesch A; Lang T; Hartl D; Hector A; Glasmacher C; Griese M
Aliment Pharmacol Ther; 2012 Aug; 36(3):266-73. PubMed ID: 22670841
[TBL] [Abstract][Full Text] [Related]
12. Ursodeoxycholic acid for cystic fibrosis-related liver disease.
Cheng K; Ashby D; Smyth R
Cochrane Database Syst Rev; 2000; (2):CD000222. PubMed ID: 10796703
[TBL] [Abstract][Full Text] [Related]
13. The role of hepatobiliary scintigraphy in cystic fibrosis.
O'Connor PJ; Southern KW; Bowler IM; Irving HC; Robinson PJ; Littlewood JM
Hepatology; 1996 Feb; 23(2):281-7. PubMed ID: 8591853
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease.
Siano M; De Gregorio F; Boggia B; Sepe A; Ferri P; Buonpensiero P; Di Pasqua A; Raia V
Dig Liver Dis; 2010 Jun; 42(6):428-31. PubMed ID: 20034860
[TBL] [Abstract][Full Text] [Related]
15. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
Lindblad A; Glaumann H; Strandvik B
Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
[TBL] [Abstract][Full Text] [Related]
17. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease.
Colombo C; Castellani MR; Balistreri WF; Seregni E; Assaisso ML; Giunta A
Hepatology; 1992 Apr; 15(4):677-84. PubMed ID: 1551646
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis.
Scher H; Bishop WP; McCray PB
Ann Pharmacother; 1997 Sep; 31(9):1003-5. PubMed ID: 9296240
[TBL] [Abstract][Full Text] [Related]
19. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis.
Smith JL; Lewindon PJ; Hoskins AC; Pereira TN; Setchell KD; O'Connell NC; Shepherd RW; Ramm GA
Hepatology; 2004 Jun; 39(6):1673-82. PubMed ID: 15185309
[TBL] [Abstract][Full Text] [Related]
20. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases.
Trauner M; Graziadei IW
Aliment Pharmacol Ther; 1999 Aug; 13(8):979-96. PubMed ID: 10468672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
